Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

- PMLiVE

Novartis receives FDA breakthrough therapy designation for rare disease med

The Swiss pharma company is eyeing approval in PNH and C3G indications

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

- PMLiVE

Novartis and smartpatient launch app experience for wet AMD patients

Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Novartis scores CHMP backing for cholesterol drug Leqvio

Potential first-in-class treatment moves closer to EU approval

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Pfizer and BioNTech’s COVID-19 vaccine begins EMA evaluation

Vaccine is the second to undergo EMA's 'rolling review' process after AstraZeneca/Oxford Uni's candidate

- PMLiVE

EMA begins rolling review of AZ’s COVID-19 vaccine candidate

Agency has started evaluating data from non-clinical laboratory studies

- PMLiVE

EMA accepts application for bluebird bio’s Lenti-D in CALD

Gene therapy could become a potentially transformative treatment for cerebral adrenoleukodystrophy

- PMLiVE

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

Deal will expand production capacity for BNT162b2 candidate

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links